- /
- Supported exchanges
- / US
- / MNKD.NASDAQ
MannKind Corp (MNKD NASDAQ) stock market data APIs
MannKind Corp Financial Data Overview
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with MannKind Corp (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get MannKind Corp data using free add-ons & libraries
Get MannKind Corp Fundamental Data
MannKind Corp Fundamental data includes:
- Net Revenue: 413 M
- EBITDA: -1 942 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-05
- EPS/Forecast: -0.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MannKind Corp News
New
Should You Buy MannKind (MNKD) After Golden Cross?
After reaching an important support level, MannKind Corporation (MNKD) could be a good stock pick from a technical perspective. MNKD recently experienced a "golden cross" event, which saw its 50-day s...
MannKind to Participate in Upcoming Investor Conferences
MannKind DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that Chief Executive Officer, Michael Castagna, and Chief ...
MannKind Corp (MNKD) Q3 2026 Earnings Call Highlights: Revenue Jumps 24% as FuroSix ReadyFlow ...
This article first appeared on GuruFocus. Release Date: November 05, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Total...
Is MannKind (MNKD) Trading At A Discount Following Its Mixed Third Quarter Results?
Why MannKind's latest quarter is drawing attention MannKind (MNKD) just released its third quarter numbers, reporting higher revenue along with a shift from profit to loss. That combination of growth...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.